Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advances in mRNA-based drug discovery in cancer immunotherapy.
Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P. Di Trani CA, et al. Expert Opin Drug Discov. 2022 Jan;17(1):41-53. doi: 10.1080/17460441.2021.1978972. Epub 2021 Sep 20. Expert Opin Drug Discov. 2022. PMID: 34496689 Review.
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Cirella A, et al. Among authors: fernandez sendin m. Pharmacol Ther. 2022 Nov;239:108189. doi: 10.1016/j.pharmthera.2022.108189. Epub 2022 Apr 14. Pharmacol Ther. 2022. PMID: 35430292 Review.
Overcoming the limitations of cytokines to improve cancer therapy.
Di Trani CA, Cirella A, Arrizabalaga L, Fernandez-Sendin M, Bella A, Aranda F, Melero I, Berraondo P. Di Trani CA, et al. Among authors: fernandez sendin m. Int Rev Cell Mol Biol. 2022;369:107-141. doi: 10.1016/bs.ircmb.2022.05.002. Epub 2022 May 30. Int Rev Cell Mol Biol. 2022. PMID: 35777862 Review.
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.
Bella Á, Arrizabalaga L, Di Trani CA, Cirella A, Fernandez-Sendin M, Gomar C, Russo-Cabrera JS, Rodríguez I, González-Gomariz J, Alvarez M, Teijeira Á, Medina-Echeverz J, Hinterberger M, Hochrein H, Melero I, Berraondo P, Aranda F. Bella Á, et al. Among authors: fernandez sendin m. Oncoimmunology. 2022 Jul 13;11(1):2098657. doi: 10.1080/2162402X.2022.2098657. eCollection 2022. Oncoimmunology. 2022. PMID: 35859732 Free PMC article.
20 results